AAO ’23: Real-World Faricimab Patterns and Improving GA Assessments
New Retina Radio by Eyetube
English - November 30, 2023 22:04 - 22 minutes - ★★★★ - 16 ratingsScience Health & Fitness Medicine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up.
And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out.
This Editorially independent content is supported with advertising.
The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up.
And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out.
This Editorially independent content is supported with advertising.